A Phase 3 Study of CS-8958 (Postexposure Prophylaxis 2011) - A randamized, double-blind, placebo-controlled study to confirm the efficacy in the prevention of influenza virus infection -

Trial Profile

A Phase 3 Study of CS-8958 (Postexposure Prophylaxis 2011) - A randamized, double-blind, placebo-controlled study to confirm the efficacy in the prevention of influenza virus infection -

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top